Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial

Fineline Cube Apr 29, 2026
Company Drug

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Fineline Cube Apr 29, 2026
Company Drug

Gan & Lee Pharmaceuticals Gains Marketing Approval for Insulin Glargine in Mexico

Fineline Cube May 24, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...

Company Deals

China’s Tigermed Taps Veeva Systems for Advanced Electronic Data Acquisition

Fineline Cube May 24, 2024

Veeva Systems, a U.S.-based life science cloud software specialist, has entered into a partnership with...

Company Drug

Keymed Biosciences’ Stapokibart Earns Priority Review for Chronic Sinusitis Treatment in China

Fineline Cube May 24, 2024

Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced that its...

Company Drug

Sino Biopharmaceutical’s Benmelstobart Shows Positive Results in RCC Combination Therapy Study

Fineline Cube May 24, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced positive...

Company Deals

Boehringer Ingelheim and Peking University Deepen Partnership with Joint Drug Research Lab

Fineline Cube May 24, 2024

Boehringer Ingelheim, a major German pharmaceutical company, has entered into an agreement with China’s Peking...

Company Deals

Eli Lilly Partners with Aktis Oncology to Advance Cancer Radiopharmaceuticals

Fineline Cube May 23, 2024

Eli Lilly and Company (NYSE: LLY) has announced a strategic partnership with Aktis Oncology, a...

Company Deals

MSD Partners with Dragonfly Therapeutics to Combine Keytruda with NK Cell Engager in Cancer Treatment

Fineline Cube May 23, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), the producer of the leading checkpoint inhibitor Keytruda...

Company Deals

Alvotech and Dr. Reddy’s Partner to Challenge Amgen’s Denosumab with Biosimilar AVT03

Fineline Cube May 23, 2024

Amgen’s (NASDAQ: AMGN) dominance in the bone treatment market with its blockbuster drugs Xgeva and...

Company Deals

Legend Biotech Gains Access to MaxCyte’s Cell Engineering Tech with New License Agreement

Fineline Cube May 23, 2024

China’s Legend Biotech Corporation (NASDAQ: LEGN) has entered into a strategic platform license (SPL) agreement...

Policy / Regulatory

China’s NMPA and NHC Tighten Control on Psychotropic Substances with New Regulations

Fineline Cube May 23, 2024

The National Medical Products Administration (NMPA) and the National Health Commission (NHC) of China have...

Company

Jiuzhou Pharmaceutical Expands Global Footprint with $9.5 Million German CRO Subsidiary

Fineline Cube May 23, 2024

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a leading Chinese pharmaceutical company, has announced plans...

Company Drug

Fosun Pharmaceutical’s Humira Biosimilar Gains New Indications with NMPA Approval

Fineline Cube May 23, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its biosimilar...

Company Drug

Simcere Pharmaceutical’s Quviviq Secures Hong Kong Marketing Approval for Insomnia Treatment

Fineline Cube May 23, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received marketing approval...

Company Drug

NK CellTech’s NK-Cell Therapy Gets Green Light from China’s NMPA for Solid Tumor Treatment

Fineline Cube May 23, 2024

NK CellTech, a Shanghai-based developer of natural killer (NK) cell therapies, has announced that it...

Company Deals Digital

C.Q. Pharmaceutical and JD.com Join Forces to Revolutionize Pharmaceutical Supply Chain

Fineline Cube May 23, 2024

C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950), a prominent Chinese pharmaceutical company, has announced a...

Company Deals

AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement

Fineline Cube May 23, 2024

HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement...

Company Deals

Fosun Diagnostics and Jointown Medical Ink Partnership to Boost Medical Supply Chain

Fineline Cube May 23, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading healthcare conglomerate in...

Company Drug

Laekna Therapeutics’ mCRPC Drug Combo Advances to Phase III with FDA Approval

Fineline Cube May 23, 2024

Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced that it...

Company Drug

Changchun High & New Technology Industries Gets Green Light for Jinnamab Clinical Trial

Fineline Cube May 23, 2024

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a leading biopharmaceutical company based...

Company Deals

Amoy Diagnostics Teams Up with Boehringer Ingelheim for CDx Developmen

Fineline Cube May 23, 2024

Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a prominent player in China’s tumor precision medicine...

Posts pagination

1 … 349 350 351 … 659

Recent updates

  • Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed
  • Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion
  • Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement
  • Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets
  • Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed

Company

Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion

Company

Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.